The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Raises $650 Million in Upsized U.S. Equity Offering
- Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
- Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
- Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
- Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo